JPH0219805B2 - - Google Patents
Info
- Publication number
- JPH0219805B2 JPH0219805B2 JP57063202A JP6320282A JPH0219805B2 JP H0219805 B2 JPH0219805 B2 JP H0219805B2 JP 57063202 A JP57063202 A JP 57063202A JP 6320282 A JP6320282 A JP 6320282A JP H0219805 B2 JPH0219805 B2 JP H0219805B2
- Authority
- JP
- Japan
- Prior art keywords
- acetal
- prostaglandin
- amount
- water
- pge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 64
- 150000003180 prostaglandins Chemical class 0.000 claims abstract description 64
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims abstract description 63
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 18
- 150000001241 acetals Chemical class 0.000 claims description 52
- 239000000243 solution Substances 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 35
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 150000004702 methyl esters Chemical class 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- MAQMEXSLUSZDQM-UHFFFAOYSA-N diethoxymethylbenzene Chemical compound CCOC(OCC)C1=CC=CC=C1 MAQMEXSLUSZDQM-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract description 23
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 39
- 239000002904 solvent Substances 0.000 description 38
- 230000000694 effects Effects 0.000 description 15
- 239000003960 organic solvent Substances 0.000 description 14
- 150000001298 alcohols Chemical class 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- -1 hydroxy fatty acids Chemical class 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 229920001515 polyalkylene glycol Polymers 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000001069 triethyl citrate Substances 0.000 description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
- 235000013769 triethyl citrate Nutrition 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000005906 dihydroxylation reaction Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- POKRQUNDSGAZIA-OALUTQOASA-N 7-[(1r,2s)-2-octylcyclopentyl]hepta-2,4-dienoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCC=CC=CC(O)=O POKRQUNDSGAZIA-OALUTQOASA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical group CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000002388 eustachian tube Anatomy 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/254,824 US4358603A (en) | 1981-04-16 | 1981-04-16 | Acetal stabilized prostaglandin compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57181054A JPS57181054A (en) | 1982-11-08 |
| JPH0219805B2 true JPH0219805B2 (enExample) | 1990-05-07 |
Family
ID=22965721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57063202A Granted JPS57181054A (en) | 1981-04-16 | 1982-04-15 | Acetal-stabilized prostaglandin composition |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4358603A (enExample) |
| EP (1) | EP0063367B1 (enExample) |
| JP (1) | JPS57181054A (enExample) |
| AT (1) | ATE9061T1 (enExample) |
| AU (1) | AU553104B2 (enExample) |
| CA (1) | CA1168155A (enExample) |
| DE (1) | DE3260600D1 (enExample) |
| HK (1) | HK43987A (enExample) |
| IE (1) | IE52854B1 (enExample) |
| MY (1) | MY8700597A (enExample) |
| NZ (1) | NZ200309A (enExample) |
| ZA (1) | ZA822578B (enExample) |
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| EP0668076B1 (en) * | 1992-08-26 | 2002-09-04 | Sucampo AG | Stabilization of a prostanoic acid compound |
| US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| ES2241133T3 (es) | 1997-04-28 | 2005-10-16 | Encysive Pharmaceuticals Inc. | Sulfamidas para el tratamiento de los trastornos inducidos por la endotelina. |
| US6362009B1 (en) | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
| US7169410B1 (en) * | 1998-05-19 | 2007-01-30 | Sdg, Inc. | Targeted liposomal drug delivery system |
| US6638977B1 (en) | 1999-11-19 | 2003-10-28 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists |
| US6677473B1 (en) | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
| US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
| JP2005509616A (ja) * | 2001-10-16 | 2005-04-14 | センジェント・セラピューティクス・インク | チロシンホスファターゼに対する有機硫黄阻害剤 |
| AUPR868201A0 (en) * | 2001-11-05 | 2001-11-29 | Thorlock International Limited | Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals |
| EP1465882B1 (en) * | 2001-12-21 | 2011-08-24 | X-Ceptor Therapeutics, Inc. | Hetrocyclic modulators of nuclear receptors |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
| ATE507210T1 (de) | 2002-03-07 | 2011-05-15 | X Ceptor Therapeutics Inc | Chinazolinon modulatoren von nukleinrezeptoren |
| US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| WO2004002476A2 (en) | 2002-06-27 | 2004-01-08 | Health Research, Inc. | Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
| AU2003249742A1 (en) | 2002-07-02 | 2004-01-23 | Health Research, Inc. | Efficient synthesis of pyropheophorbide a and its derivatives |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| ZA200507978B (en) | 2003-03-05 | 2007-03-28 | Halozyme Inc | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| JP4847868B2 (ja) * | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
| WO2005000298A2 (en) * | 2003-06-03 | 2005-01-06 | Novartis Ag | 5-membered heterocycle-based p-38 inhibitors |
| EP1911754B1 (en) | 2003-08-13 | 2013-10-09 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US20050203184A1 (en) * | 2003-09-10 | 2005-09-15 | Petasis Nicos A. | Benzo lipoxin analogues |
| US7420000B2 (en) | 2003-09-10 | 2008-09-02 | University Of Southern California | Amino phosphonate and amino bis-phosphonate derivatives |
| WO2005032544A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Treatment of mitochondrial diseases |
| US20050148534A1 (en) * | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
| US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| CA2566688A1 (en) | 2004-05-20 | 2005-12-01 | The Scripps Research Institute | Transthyretin stabilization |
| WO2006009876A2 (en) * | 2004-06-17 | 2006-01-26 | Cengent Therapeutics, Inc. | Trisubstituted nitrogen modulators of tyrosine phosphatases |
| JP2008505916A (ja) * | 2004-07-09 | 2008-02-28 | メタバシス・セラピューティクス・インコーポレイテッド | チロシンホスファターゼの酸素／窒素複素環阻害剤 |
| WO2006017295A2 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
| EP1841749A1 (en) * | 2004-09-02 | 2007-10-10 | Metabasis Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
| AU2005287137B2 (en) | 2004-09-17 | 2012-03-22 | Foldrx Pharmaceuticals, Inc. | Compounds, compositions and methods of inhibiting a-synuclein toxicity |
| WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
| CN101189249B (zh) | 2005-04-01 | 2013-04-17 | 加利福尼亚大学董事会 | 膦酰基-戊-2-烯-1-基核苷和类似物 |
| US8193357B2 (en) * | 2005-06-17 | 2012-06-05 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds |
| US20100098640A1 (en) * | 2005-06-20 | 2010-04-22 | Cohen Seth M | Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| WO2008051197A2 (en) * | 2005-09-20 | 2008-05-02 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8138361B2 (en) * | 2005-12-28 | 2012-03-20 | The Trustees Of The University Of Pennsylvania | C-10 carbamates of taxanes |
| RU2440144C2 (ru) * | 2006-01-24 | 2012-01-20 | Р-Тек Уено, Лтд. | Фармацевтическая композиция, содержащая бициклическое соединение, и способ стабилизации бициклического соединения |
| CA2647543A1 (en) * | 2006-03-29 | 2007-11-08 | Foldrx Pharmaceuticals, Inc. | Inhibition of alpha-synuclein toxicity |
| TWI405771B (zh) | 2006-08-28 | 2013-08-21 | Kyowa Hakko Kirin Co Ltd | 具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體 |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CA2666138A1 (en) | 2006-10-09 | 2008-05-08 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2010508307A (ja) | 2006-10-31 | 2010-03-18 | 武田薬品工業株式会社 | Ｍａｐｋ／ｅｒｋキナーゼ阻害剤 |
| US20110201818A1 (en) | 2007-09-25 | 2011-08-18 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| US20090264421A1 (en) * | 2007-10-05 | 2009-10-22 | Bible Keith C | Methods and Compositions for Treating Cancer |
| US8426587B2 (en) * | 2007-11-21 | 2013-04-23 | Pharmaxis Ltd. | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor |
| DK2222636T3 (da) | 2007-12-21 | 2013-06-03 | Ligand Pharm Inc | Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| WO2010008847A2 (en) | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Pi3k/m tor inhibitors |
| WO2010002972A1 (en) | 2008-07-01 | 2010-01-07 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| WO2010080835A1 (en) | 2009-01-06 | 2010-07-15 | Curemark Llc | Compositions and methods for the treatment or the prevention oral infections by e. coli |
| ES2578618T3 (es) | 2009-01-06 | 2016-07-28 | Curelon Llc | Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus |
| US8669249B2 (en) | 2009-03-27 | 2014-03-11 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| EP2459561A1 (en) | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| US8404728B2 (en) | 2009-07-30 | 2013-03-26 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| EP2499282B1 (en) | 2009-11-09 | 2015-04-22 | NeuroGenetic Pharmaceuticals, Inc. | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor |
| WO2011069002A1 (en) | 2009-12-02 | 2011-06-09 | Alquest Therapeutics, Inc. | Organoselenium compounds and uses thereof |
| EP2515654A4 (en) * | 2009-12-23 | 2013-04-24 | Map Pharmaceuticals Inc | NEW ERGOLINANALOGA |
| US8802695B2 (en) | 2010-02-03 | 2014-08-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| US9403815B2 (en) | 2010-06-24 | 2016-08-02 | The Regents Of The University Of California | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms |
| EP2701733B1 (en) | 2011-04-21 | 2019-04-03 | Curemark, LLC | Compounds for the treatment of neuropsychiatric disorders |
| WO2012177962A1 (en) | 2011-06-23 | 2012-12-27 | Map Pharmaceuticals, Inc. | Novel fluoroergoline analogs |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| CA2859173A1 (en) | 2011-12-19 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
| SG11201403433PA (en) | 2011-12-21 | 2014-07-30 | Map Pharmaceuticals Inc | Novel neuromodulatory compounds |
| US9567316B2 (en) | 2012-03-07 | 2017-02-14 | The Mclean Hospital Corporation | Aminoquinoline derivatives and uses thereof |
| DK2844637T5 (en) | 2012-05-02 | 2018-08-13 | Boehringer Ingelheim Int | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS BY SSAO AND USES THEREOF |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| EP3406598B1 (en) | 2012-06-14 | 2020-01-29 | Mayo Foundation for Medical Education and Research | Pyrazole derivatives as inhibitors of stat3 |
| US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
| US8551535B1 (en) | 2012-08-06 | 2013-10-08 | Sarah McCann | Homeopathic remedies and methods for enhancing weight loss |
| US9074186B2 (en) | 2012-08-15 | 2015-07-07 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
| US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| WO2014100354A1 (en) | 2012-12-21 | 2014-06-26 | Map Pharmaceuticals, Inc. | Novel methysergide derivatives |
| CA2902232C (en) | 2013-02-22 | 2020-12-29 | University Of Southern California | Methods for treatment of ophthalmic diseases and disorders |
| EP2968296B1 (en) | 2013-03-12 | 2020-09-02 | The Regents of the University of California | Gamma-secretase modulators |
| EP2967049B1 (en) | 2013-03-15 | 2020-09-02 | University Of Southern California | Methods, compounds, and compositions for the treatment of angiotensin-related diseases |
| SG10201708143QA (en) | 2013-06-06 | 2017-11-29 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2016025129A1 (en) | 2014-08-14 | 2016-02-18 | Alhamadsheh Mamoun M | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
| EP3212633B1 (en) | 2014-10-31 | 2019-12-04 | The General Hospital Corporation | Potent gamma-secretase modulators |
| PT3800202T (pt) | 2014-12-11 | 2023-01-05 | Pf Medicament | Anticorpos anti-c10orf54 e suas utilizações |
| EP3247357A4 (en) | 2015-01-20 | 2018-07-11 | Xoc Pharmaceuticals, Inc | Isoergoline compounds and uses thereof |
| CA2974117A1 (en) | 2015-01-20 | 2016-07-28 | Xoc Pharmaceuticals, Inc. | Ergoline compounds and uses thereof |
| WO2016139482A1 (en) | 2015-03-03 | 2016-09-09 | Kymab Limited | Antibodies, uses & methods |
| WO2016176617A2 (en) | 2015-04-29 | 2016-11-03 | New York University | Method for treating high-grade gliomas |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| WO2017096323A1 (en) | 2015-12-02 | 2017-06-08 | Astraea Therapeutics, Llc | Piperidinyl nociceptin receptor compounds |
| KR102742235B1 (ko) | 2016-02-12 | 2024-12-13 | 파맥시스 엘티디 | 라이실 옥시다제의 할로알릴아민 인돌 및 아자인돌 유도체 억제제 및 이의 용도 |
| US10960013B2 (en) | 2016-03-04 | 2021-03-30 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders |
| EP3426352A4 (en) | 2016-03-08 | 2019-11-13 | Los Gatos Pharmaceuticals, Inc. | CAMPTOTHECIN DERIVATIVES AND USES THEREOF |
| US10064855B2 (en) | 2016-03-08 | 2018-09-04 | Los Gatos Pharmaceuticals, Inc. | Composite nanoparticles and uses thereof |
| US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
| EP3454904B1 (en) | 2016-05-13 | 2022-12-14 | Institut Pasteur | Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology |
| WO2018035281A1 (en) | 2016-08-17 | 2018-02-22 | North Carolina State University | Northern-southern route to synthesis of bacteriochlorins |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018089692A1 (en) | 2016-11-09 | 2018-05-17 | Phloronol, Inc. | Eckol derivatives, methods of synthesis and uses thereof |
| US10836774B2 (en) | 2016-11-30 | 2020-11-17 | North Carolina State University | Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds |
| JP7157752B2 (ja) | 2017-02-17 | 2022-10-20 | エイドス セラピューティクス，インコーポレイティド | Ａｇ－１０、その中間体及びその塩の調製方法 |
| US12226464B2 (en) | 2017-04-10 | 2025-02-18 | Curemark, Llc | Compositions for treating addiction |
| US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| BR112019025420A2 (pt) | 2017-06-01 | 2020-06-16 | Xoc Pharmaceuticals, Inc. | Compostos policíclicos e usos destes |
| EP4265257A1 (en) | 2017-09-01 | 2023-10-25 | East Carolina University | Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer |
| US20190216751A1 (en) | 2017-11-15 | 2019-07-18 | California State University Northridge | Compositions and Methods for the Treatment and Prevention of Cancer |
| CN112218632A (zh) | 2018-03-23 | 2021-01-12 | 文涵治疗有限公司 | 用ag10治疗ttr淀粉样变性的方法 |
| EP3824287A1 (en) | 2018-07-20 | 2021-05-26 | Pierre Fabre Médicament | Receptor for vista |
| AR115906A1 (es) | 2018-08-03 | 2021-03-10 | Pharmaxis Ltd | Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas |
| UA128256C2 (uk) | 2018-08-17 | 2024-05-22 | Ейдос Терапьютікс, Інк. | Препарати ag10 |
| WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
| US11447468B2 (en) | 2019-02-06 | 2022-09-20 | Dice Alpha, Inc. | IL-17 ligands and uses thereof |
| EP3956309A4 (en) | 2019-04-19 | 2023-06-07 | Ligand Pharmaceuticals Inc. | CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND |
| EP3959292B1 (en) | 2019-05-20 | 2025-07-02 | NIRvana Sciences Inc. | Narrow emission dyes, compositions comprising same, and methods for making and using same |
| CN114222803B (zh) | 2019-05-20 | 2025-01-07 | 尼尔瓦纳科学股份有限公司 | 窄发射染料、包含其的组合物以及制备和使用其的方法 |
| WO2021055376A1 (en) | 2019-09-16 | 2021-03-25 | Dice Alpha, Inc. | Il-17a modulators and uses thereof |
| WO2022006228A1 (en) | 2020-06-30 | 2022-01-06 | Prosetta Biosciences, Inc. | Isoquinoline derivatives, methods of synthesis and uses thereof |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| IL305752A (en) | 2021-03-10 | 2023-11-01 | Dice Molecules Sv Inc | INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES |
| AU2022368836A1 (en) | 2021-10-22 | 2024-05-02 | Prosetta Biosciences, Inc. | Novel host-targeted pan-respiratory antiviral small molecule therapeutics |
| US11932665B2 (en) | 2022-01-03 | 2024-03-19 | Lilac Therapeutics, Inc. | Cyclic thiol prodrugs |
| EP4433040A4 (en) | 2022-01-03 | 2025-11-12 | Lilac Therapeutics Inc | ACYCLIC THIOL PRODRUGS |
| CN118922189A (zh) | 2022-03-02 | 2024-11-08 | 线粒体能量有限公司 | 衍生自烟酸和核糖的新型前药 |
| GB2619907A (en) | 2022-04-01 | 2023-12-27 | Kanna Health Ltd | Novel crystalline salt forms of mesembrine |
| GB2636969A (en) | 2023-11-24 | 2025-07-09 | Ontrack Therapeutics Ltd | Novel crystalline salt forms |
| WO2025201633A1 (en) | 2024-03-26 | 2025-10-02 | Chen Gefei | An agent for reducing amyloid formation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3749800A (en) * | 1971-11-01 | 1973-07-31 | Upjohn Co | Stable composition for dispensing pge2 |
| US3833612A (en) * | 1971-11-24 | 1974-09-03 | Merck & Co Inc | Derivatives of 5-oxo-1 beta-cyclopentane-heptanoic acid,5-ethylene acetals |
| US4178457A (en) * | 1978-07-10 | 1979-12-11 | Syntex (U.S.A.) Inc. | (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof |
| US4178454A (en) * | 1978-10-11 | 1979-12-11 | Toray Industries, Inc. | Stabilized prostaglandin E composition |
-
1981
- 1981-04-16 US US06/254,824 patent/US4358603A/en not_active Expired - Fee Related
-
1982
- 1982-04-15 DE DE8282103196T patent/DE3260600D1/de not_active Expired
- 1982-04-15 JP JP57063202A patent/JPS57181054A/ja active Granted
- 1982-04-15 AT AT82103196T patent/ATE9061T1/de not_active IP Right Cessation
- 1982-04-15 NZ NZ200309A patent/NZ200309A/en unknown
- 1982-04-15 AU AU82635/82A patent/AU553104B2/en not_active Ceased
- 1982-04-15 IE IE889/82A patent/IE52854B1/en unknown
- 1982-04-15 EP EP82103196A patent/EP0063367B1/en not_active Expired
- 1982-04-15 CA CA000401023A patent/CA1168155A/en not_active Expired
- 1982-04-15 ZA ZA822578A patent/ZA822578B/xx unknown
-
1987
- 1987-06-04 HK HK439/87A patent/HK43987A/xx unknown
- 1987-12-30 MY MY597/87A patent/MY8700597A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE820889L (en) | 1982-10-16 |
| DE3260600D1 (en) | 1984-09-27 |
| EP0063367B1 (en) | 1984-08-22 |
| JPS57181054A (en) | 1982-11-08 |
| EP0063367A1 (en) | 1982-10-27 |
| ZA822578B (en) | 1983-11-30 |
| AU8263582A (en) | 1982-10-21 |
| HK43987A (en) | 1987-06-12 |
| MY8700597A (en) | 1987-12-31 |
| CA1168155A (en) | 1984-05-29 |
| NZ200309A (en) | 1985-03-20 |
| IE52854B1 (en) | 1988-03-30 |
| AU553104B2 (en) | 1986-07-03 |
| US4358603A (en) | 1982-11-09 |
| ATE9061T1 (de) | 1984-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0219805B2 (enExample) | ||
| CA1203172A (en) | Propylene glycol diester solutions of pge-type compounds | |
| US4328245A (en) | Carbonate diester solutions of PGE-type compounds | |
| US4410545A (en) | Carbonate diester solutions of PGE-type compounds | |
| ES2282408T3 (es) | 15-ceto-prostaglandina para el tratamiento de estreñimiento por farmaco. | |
| BRPI0707334A2 (pt) | formulação de cápsula de gelatila mole e método para estabilização de um composto 15-cetoprostaglandina | |
| IE51637B1 (en) | Pharmaceutical preparation | |
| ES2310013T3 (es) | Uso de compuestos de 15-ceto-prostaglandina e como antagonistas de endotelina. | |
| BRPI0317740B1 (pt) | uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1 | |
| JP5427029B2 (ja) | 消化管の重炭酸分泌を促進するための方法および組成物 | |
| JP5390519B2 (ja) | １１−デオキシ−プロスタグランジン化合物を含む医薬組成物およびその安定化方法 | |
| JPH0144172B2 (enExample) | ||
| TWI594751B (zh) | 治療帶有腹瀉之腸躁症之方法 | |
| US6710081B1 (en) | Erection insufficiency remedies | |
| JPS629091B2 (enExample) | ||
| EP0410646A2 (en) | Treatment of hyperlipidemia with 15-keto-prostaglandin compounds | |
| TW201705952A (zh) | 包含脂肪酸衍生物的醫藥組成物 | |
| AU2013203903A1 (en) | Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound |